leadf
logo-loader
viewPharmaxis Ltd

Pharmaxis CEO says US FDA approval for Bronchitol® is 'big day in company's history'

Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips speaks to Proactive's Andrew Scott following the news the US FDA has approved its cystic fibrosis treatment Bronchitol®. The milestone clears Bronchitol for sale in the US as an add‐on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients 18 years of age and older.

Quick facts: Pharmaxis Ltd

Price: 0.09 AUD

ASX:PXS
Market: ASX
Market Cap: $35.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read